| General JP Morgan Healthcare Conference Marked by Hesitant Optimism by Dr. Audrey Erbes, Principal of Erbes & Associates, submitted 1/16/10 In this article, Dr. Audrey Erbes gave a recap of this year's JP Morgan Healthcare Conference. |
| Contract Research DNA Damage Signal and Repair Networks as Targets for Novel Cancer Therapy by Dr. Jiwu Wang, CEO of Allele Biotechnology & Pharmaceuticals, Inc., submitted 11/18/09 By targeting DNA damage signaling and repair factors through synthetic lethal screens using RNAi, novel cancer therapy targets as well as drug candidates may be identified. This type of drug screening is an element of the National Cancer Institute’s research plan and should be of interest to biotech and pharmaceutical companies R&D efforts. |
| Careers and Employment Educational Options for Breaking into Regulatory Medical Writing by Mitch Gordon, submitted 11/14/09 Writers are particularly interested now in regulatory writing. This is the kind of writing that US drug or medical device companies use to apply for FDA approval of their products. It is the most lucrative and sought-after branch of medical writing, but it is also difficult to break into. In this article, Mitch shares with viewers some tips for breaking into this field. |
| Careers and Employment Marketing Your Career -- Becoming a Proactive Job Seeker by Mitch Gordon, submitted 11/13/09 The global economic crisis has hurt all of us in various ways. If you’ve been laid off in recent months, you're feeling its effects very directly. It’s discouraging to try to get a job while the news reports continue to announce massive new layoffs, and the resumes you send out lie buried in stacks on hiring managers' desks. However, your job loss can be an opportunity to reassess your career, figure out what you want to do next, and take more control of your future. |
| General The Nicholas Conor Institute Partners with Industry to Bring New Discoveries for Childhood Cancer to the Clinic by Dr. Adrienne Brown, submitted 11/6/09 The Nicholas Conor Institute for Pediatric Cancer partners with industry, and the biomedical community to discover and commercialize child-specific therapeutics and diagnostics. The Institute identifies new technologies in the genomics and proteomics fields and supports the research and development of innovative therapies and diagnostics. The Institute aims to build better tools in the fight against childhood cancer with the long-term goal of developing individualized therapies. |
| Careers and Employment Tips for Transitioning into Bioscience by Dr. Audrey Erbes, Principal of Erbes & Associates, submitted 11/1/09 In this article, Dr. Audrey Erbes makes some recommendations to those interested in transitioning functionally within the life science industry or moving from outside to inside the industry. |
| Pharma/Biotech Start-Up Targeting Orphan Nuclear Receptors by Dr. Scott Thacher, CEO and Director of Orphagen Pharmaceuticals, submitted 10/29/09 Orphagen Pharmaceuticals is a privately owned, emerging pharmaceutical company located in San Diego, California. Orphagen focuses on major unmet medical needs by developing innovative small molecule drugs targeting orphan nuclear receptors. The company has hits and leads to several orphan nuclear receptors in various stages of preclinical discovery research. To date, Orphagen has secured over $ 2.7 M in external grant funding and has recently entered into a major partnership for pre-clinical and clinical development of one of its targets. |
| Pharma/Biotech Start-Up Biotic Labs: Driving the Innovation of High Performance Drug Delivery by Dr. Erik Pierstorff, Chief Technology Officer and Co-Founder of Biotic Laboratories, submitted 9/16/09 Biotic Laboratories is an early stage company focused on the development of implantable medical devices for drug delivery. This exciting and innovative technology aims at reducing the toxic side effects of therapeutic drugs and reducing the medical costs associated with drug administration. |
| Contract Research Integrated Approach to Formulation Development and Manufacturing Streamlines Protein Surfactant Screening by Dr. Byeong S. Chang, Chief Scientific Officer of Symyx, submitted 9/15/09 Ascertaining the best formulation for clinical development is often a difficult process. Traditional trial-and-error approaches often limit outcomes, preventing scientists from seeing alternate or unexpected possibilities. Symyx specializes in information-driven approaches to formulation development and manufacturing. Specifically, the appropriate use of high-productivity research tools and scientific informatics can help streamline formulation work. |
